Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.41
ABT's Cash-to-Debt is ranked lower than
81% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. ABT: 0.41 )
Ranked among companies with meaningful Cash-to-Debt only.
ABT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.28 Max: N/A
Current: 0.41
Equity-to-Asset 0.44
ABT's Equity-to-Asset is ranked lower than
75% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ABT: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
ABT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.47 Max: 0.59
Current: 0.44
0.37
0.59
Interest Coverage 2.92
ABT's Interest Coverage is ranked lower than
85% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 73.23 vs. ABT: 2.92 )
Ranked among companies with meaningful Interest Coverage only.
ABT' s Interest Coverage Range Over the Past 10 Years
Min: 4.25  Med: 10.89 Max: 17.59
Current: 2.92
4.25
17.59
Piotroski F-Score: 5
Altman Z-Score: 2.45
Beneish M-Score: -2.42
WACC vs ROIC
10.24%
8.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 8.77
ABT's Operating Margin % is ranked higher than
71% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.45 vs. ABT: 8.77 )
Ranked among companies with meaningful Operating Margin % only.
ABT' s Operating Margin % Range Over the Past 10 Years
Min: 7.14  Med: 14.66 Max: 20.27
Current: 8.77
7.14
20.27
Net Margin % 4.96
ABT's Net Margin % is ranked higher than
68% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. ABT: 4.96 )
Ranked among companies with meaningful Net Margin % only.
ABT' s Net Margin % Range Over the Past 10 Years
Min: 6.71  Med: 15.23 Max: 31.3
Current: 4.96
6.71
31.3
ROE % 4.69
ABT's ROE % is ranked higher than
60% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. ABT: 4.69 )
Ranked among companies with meaningful ROE % only.
ABT' s ROE % Range Over the Past 10 Years
Min: 6.71  Med: 20.51 Max: 28.49
Current: 4.69
6.71
28.49
ROA % 2.14
ABT's ROA % is ranked higher than
60% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 0.49 vs. ABT: 2.14 )
Ranked among companies with meaningful ROA % only.
ABT' s ROA % Range Over the Past 10 Years
Min: 2.98  Med: 8.77 Max: 12.12
Current: 2.14
2.98
12.12
ROC (Joel Greenblatt) % 25.63
ABT's ROC (Joel Greenblatt) % is ranked higher than
74% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 6.15 vs. ABT: 25.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ABT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0.81  Med: 33.56 Max: 65.75
Current: 25.63
0.81
65.75
3-Year Revenue Growth Rate 4.00
ABT's 3-Year Revenue Growth Rate is ranked lower than
54% of the 239 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. ABT: 4.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ABT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.9  Med: 9.7 Max: 15.2
Current: 4
-17.9
15.2
3-Year EBITDA Growth Rate -4.60
ABT's 3-Year EBITDA Growth Rate is ranked lower than
70% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 6.30 vs. ABT: -4.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ABT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34  Med: 9.7 Max: 31.6
Current: -4.6
-34
31.6
3-Year EPS without NRI Growth Rate -17.40
ABT's 3-Year EPS without NRI Growth Rate is ranked lower than
74% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. ABT: -17.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ABT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -65.6  Med: 11.9 Max: 125.5
Current: -17.4
-65.6
125.5
GuruFocus has detected 5 Warning Signs with Abbott Laboratories $ABT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABT's 30-Y Financials

Financials (Next Earnings Date: 2017-10-20 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ABT Guru Trades in Q3 2016

Steven Cohen 606,700 sh (New)
Jim Simons 657,300 sh (New)
Stanley Druckenmiller 1,068,000 sh (+177.11%)
Mairs and Power 1,089,562 sh (+168.05%)
Jeremy Grantham 4,510,348 sh (+3.80%)
Ken Fisher 12,435 sh (+0.39%)
Mario Gabelli 13,695 sh (+0.07%)
Vanguard Health Care Fund 10,508,900 sh (unchged)
Dodge & Cox 29,268 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Tom Russo 16,400 sh (unchged)
Steven Cohen 200,000 sh (unchged)
David Carlson 420,000 sh (unchged)
Joel Greenblatt Sold Out
Spiros Segalas Sold Out
Jeff Auxier 78,622 sh (-0.06%)
John Buckingham 133,239 sh (-0.25%)
Diamond Hill Capital 11,875,781 sh (-0.78%)
Murray Stahl 22,628 sh (-1.52%)
Manning & Napier Advisors, Inc 149,363 sh (-1.88%)
PRIMECAP Management 15,720,699 sh (-4.60%)
Richard Pzena 5,017,660 sh (-5.81%)
Pioneer Investments 908,362 sh (-7.21%)
George Soros 259,181 sh (-21.26%)
Paul Tudor Jones 16,600 sh (-36.88%)
Ray Dalio 62,000 sh (-40.44%)
First Eagle Investment 1,271,914 sh (-57.24%)
» More
Q4 2016

ABT Guru Trades in Q4 2016

Keeley Asset Management Corp 35,610 sh (New)
Joel Greenblatt 1,010,598 sh (New)
Jim Simons 2,980,400 sh (+353.43%)
Ray Dalio 80,200 sh (+29.35%)
Mairs and Power 1,333,036 sh (+22.35%)
Ken Fisher 14,794 sh (+18.97%)
Diamond Hill Capital 12,488,011 sh (+5.16%)
Manning & Napier Advisors, Inc 154,272 sh (+3.29%)
Vanguard Health Care Fund 10,758,900 sh (+2.38%)
Paul Tudor Jones 16,800 sh (+1.20%)
Richard Pzena 5,049,688 sh (+0.64%)
Jeff Auxier 78,664 sh (+0.05%)
Dodge & Cox 29,268 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Tom Russo 16,400 sh (unchged)
David Carlson 420,000 sh (unchged)
First Eagle Investment Sold Out
Steven Cohen Sold Out
Stanley Druckenmiller Sold Out
Pioneer Investments Sold Out
John Buckingham 132,868 sh (-0.28%)
Murray Stahl 22,528 sh (-0.44%)
Mario Gabelli 13,625 sh (-0.51%)
Jeremy Grantham 4,484,944 sh (-0.56%)
PRIMECAP Management 14,859,619 sh (-5.48%)
George Soros 229,181 sh (-11.57%)
» More
Q1 2017

ABT Guru Trades in Q1 2017

Mairs and Power 4,270,907 sh (+220.39%)
Mario Gabelli 43,633 sh (+220.24%)
Vanguard Health Care Fund 17,608,199 sh (+63.66%)
Jeff Auxier 108,013 sh (+37.31%)
Manning & Napier Advisors, Inc 194,870 sh (+26.32%)
Ken Fisher 16,656 sh (+12.59%)
Jeremy Grantham 5,008,798 sh (+11.68%)
Murray Stahl 23,728 sh (+5.33%)
Jim Simons 3,124,266 sh (+4.83%)
John Buckingham 133,698 sh (+0.62%)
Dodge & Cox 29,268 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Tom Russo 16,400 sh (unchged)
David Carlson 420,000 sh (unchged)
George Soros Sold Out
Ray Dalio Sold Out
PRIMECAP Management 14,730,964 sh (-0.87%)
Diamond Hill Capital 12,291,387 sh (-1.57%)
Richard Pzena 2,922,096 sh (-42.13%)
Paul Tudor Jones 8,900 sh (-47.02%)
Joel Greenblatt 399,925 sh (-60.43%)
» More
Q2 2017

ABT Guru Trades in Q2 2017

Ken Fisher 343,410 sh (+1961.78%)
Mario Gabelli 67,633 sh (+55.00%)
Vanguard Health Care Fund 21,432,294 sh (+21.72%)
Mairs and Power 4,528,554 sh (+6.03%)
Jeremy Grantham 5,251,959 sh (+4.85%)
Murray Stahl 24,475 sh (+3.15%)
Tom Russo 16,600 sh (+1.22%)
PRIMECAP Management 14,883,403 sh (+1.03%)
Jeff Auxier 108,314 sh (+0.28%)
Robert Bruce 230,915 sh (unchged)
Dodge & Cox 29,268 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
John Buckingham 133,497 sh (-0.15%)
Diamond Hill Capital 11,964,081 sh (-2.66%)
Richard Pzena 2,298,718 sh (-21.33%)
David Carlson 200,000 sh (-52.38%)
Jim Simons 1,065,566 sh (-65.89%)
» More
» Details

Insider Trades

Latest Guru Trades with ABT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-06-30 Add 21.72%0.4%$42.67 - $49.27 $ 48.748%21,432,294
Richard Pzena 2017-06-30 Reduce -21.33%0.16%$42.67 - $49.27 $ 48.748%2,298,718
Ken Fisher 2017-06-30 Add 1961.78%0.03%$42.67 - $49.27 $ 48.748%343,410
Mario Gabelli 2017-06-30 Add 55.00%0.01%$42.67 - $49.27 $ 48.748%67,633
Joel Greenblatt 2017-06-30 Sold Out 0.23%$42.67 - $49.27 $ 48.748%0
Vanguard Health Care Fund 2017-03-31 Add 63.66%0.68%$39.05 - $45.72 $ 48.7413%17,608,199
Richard Pzena 2017-03-31 Reduce -42.13%0.47%$39.05 - $45.72 $ 48.7413%2,922,096
Joel Greenblatt 2017-03-31 Reduce -60.43%0.3%$39.05 - $45.72 $ 48.7413%399,925
Mario Gabelli 2017-03-31 Add 220.24%0.01%$39.05 - $45.72 $ 48.7413%43,633
Ken Fisher 2017-03-31 Add 12.59%$39.05 - $45.72 $ 48.7413%16,656
George Soros 2017-03-31 Sold Out 0.29%$39.05 - $45.72 $ 48.7413%0
Vanguard Health Care Fund 2016-12-31 Add 2.38%0.02%$37.6 - $43.5 $ 48.7423%10,758,900
Richard Pzena 2016-12-31 Add 0.64%0.01%$37.6 - $43.5 $ 48.7423%5,049,688
Joel Greenblatt 2016-12-31 New Buy0.5%$37.6 - $43.5 $ 48.7423%1,010,598
George Soros 2016-12-31 Reduce -11.57%0.05%$37.6 - $43.5 $ 48.7423%229,181
Keeley Asset Management Corp 2016-12-31 New Buy0.06%$37.6 - $43.5 $ 48.7423%35,610
Ken Fisher 2016-12-31 Add 18.97%$37.6 - $43.5 $ 48.7423%14,794
Mario Gabelli 2016-12-31 Reduce -0.51%$37.6 - $43.5 $ 48.7423%13,625
First Eagle Investment 2016-12-31 Sold Out 0.14%$37.6 - $43.5 $ 48.7423%0
Richard Pzena 2016-09-30 Reduce -5.81%0.08%$39.44 - $45.29 $ 48.7414%5,017,660
First Eagle Investment 2016-09-30 Reduce -57.24%0.17%$39.44 - $45.29 $ 48.7414%1,271,914
George Soros 2016-09-30 Reduce -21.26%0.09%$39.44 - $45.29 $ 48.7414%259,181
Mario Gabelli 2016-09-30 Add 0.07%$39.44 - $45.29 $ 48.7414%13,695
Ken Fisher 2016-09-30 Add 0.39%$39.44 - $45.29 $ 48.7414%12,435
Joel Greenblatt 2016-09-30 Sold Out 0.06%$39.44 - $45.29 $ 48.7414%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NYSE:SYK, NYSE:BSX, NAS:ISRG, NYSE:EW, NYSE:ZBH, NAS:ALGN, NYSE:TFX, NYSE:VAR, NAS:ABMD, NAS:MASI, NAS:IART, NAS:NUVA, NYSE:PEN, NYSE:GMED, NYSE:NVRO, NAS:INGN, NAS:SPNC, NAS:MDXG, NYSE:ITGR, NAS:CNMD » details
Traded in other countries:ABT.Argentina, ABTT34.Brazil, ABT.Chile, ABL.Germany, ABT.Mexico, ABT.Switzerland, 0Q15.UK,
Headquarter Location:USA
Abbott Laboratories is a health care company that manufactures medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs.

Abbott manufactures and markets medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, coronary stents, catheters, infant formula, nutritional liquids for adults, vessel closure devices, and Lasik equipment. Abbott derives approximately 60% of sales outside the United States.

Guru Investment Theses on Abbott Laboratories

Keeley Funds Comments on Abbott Labs - Aug 14, 2017

Abbott Labs (NYSE:ABT) is a large, multinational health care products company focusing on pharmaceuticals, diagnostic and nutritional products. The company reported a nice quarter beating estimates for both sales and earnings, and continued to execute well on the integration of recently acquired St. Jude Medical. Abbott also cleared the last hurdle to complete the long-delayed purchase of Alere (ALR) which should close in the third quarter of 2017.



From Keeley All Cap Value Fund second quarter 2017 shareholder commentary.



Check out Keeley Asset Management Corp latest stock trades

John Rogers Comments on Abbott Laboratories - Aug 18, 2016

In addition, cardiovascular muscle devices maker St. Jude Medical, Inc. (NYSE:STJ) popped +42.39% after a takeout offer. Specifically, Abbott Laboratories (NYSE:ABT) offered $ 46.75 in cash and 0.9 shares of Abbott stock for each share of St. Jude. The stock jumped more than 25% on the news of the offering.

From John Rogers (Trades, Portfolio)' second quarter 2016 market commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about Abbott Laboratories

Analysts Release New Ratings on Health Care Stocks Raymond James, Citigroup and Morgan Stanley evaluate health care companies
Analysts recently released new ratings on some health care companies. Read more...
Preferred Stock Purchase Offer Extended Abbott Labs needs extra time to complete the merger with Alere
Abbott Laboratories (NYSE:ABT) informed the market through the PR Newswire Monday that it has extended its offer to buy all of Alere Inc.'s (NYSE:ALR) preferred stock. Read more...
North West London Pathology and Abbott Partner for Diagnostics Products and Services, including Alinity™, in Three NHS Trusts
Keeley Funds Comments on Abbott Labs Guru stock highlight
Abbott Labs (NYSE:ABT) is a large, multinational health care products company focusing on pharmaceuticals, diagnostic and nutritional products. The company reported a nice quarter beating estimates for both sales and earnings, and continued to execute well on the integration of recently acquired St. Jude Medical. Abbott also cleared the last hurdle to complete the long-delayed purchase of Alere (ALR) which should close in the third quarter of 2017. Read more...
Abbott Announces Extension of Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc.
The Cost of Malnutrition: Study Shows Nutrition Program Could Save Hospitals up to $3,800 per Patient
Vanguard Health Care Fund Gains 4 International Stocks in 2nd Quarter 2 positions are in newly public companies
Vanguard Health Care Fund (Trades, Portfolio) portfolio manager Jean Hynes invested in four international health care companies during the second quarter. Her new holdings are in Sysmex Corp. (TSE:6869), Terumo Corp. (TSE:4543), WuXi Biologics (Cayman) Inc. (HKSE:02269) and Idorsia Ltd. (XSWX:IDIA). Read more...
Alere Reports 2nd Quarter Company posts $92.7 million net loss
Alere Inc. (NYSE:ALR), the diagnostic tests manufacturer being acquired by Abbott Laboratories (NYSE:ABT) for $5.3 billion, delivered its financial results for the second quarter of 2017 on Aug. 3. Read more...
Abbott Laboratories Releases 2nd-Quarter Figures The medical devices segment drove revenue growth
Abbott Laboratories (NYSE:ABT) released its second-quarter 2017 results on July 20. Read more...
What's Behind Thursday's Morning Movements? 3 stocks are moving on the back of earnings reports
Stocks traded slightly in the green ahead of earnings from Abbott Laboratories (NYSE:ABT), American Express Co. (NYSE:AXP), Bank of New York Mellon Corp. (NYSE:BK), eBay Inc. (NASDAQ:EBAY), Intuitive Surgical Inc. (NASDAQ:ISRG), Microsoft Corp. (NASDAQ:MSFT), Philip Morris International Inc. (NYSE:PM), Sherwin-Williams Co. (NYSE:SHW), T-Mobile US Inc. (NASDAQ:TMUS), Union Pacific Corp. (NYSE:UNP), Qualcomm Inc. (NASDAQ:QCOM) and Visa Inc. (NYSE:V). Read more...

Ratios

vs
industry
vs
history
PE Ratio 68.65
ABT's PE Ratio is ranked lower than
69% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.71 vs. ABT: 68.65 )
Ranked among companies with meaningful PE Ratio only.
ABT' s PE Ratio Range Over the Past 10 Years
Min: 5.78  Med: 11.41 Max: 71.61
Current: 68.65
5.78
71.61
Forward PE Ratio 19.76
ABT's Forward PE Ratio is ranked higher than
78% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 25.64 vs. ABT: 19.76 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 76.16
ABT's PE Ratio without NRI is ranked lower than
70% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 31.10 vs. ABT: 76.16 )
Ranked among companies with meaningful PE Ratio without NRI only.
ABT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.93  Med: 25.29 Max: 250.57
Current: 76.16
5.93
250.57
Price-to-Owner-Earnings 42.31
ABT's Price-to-Owner-Earnings is ranked lower than
58% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 36.31 vs. ABT: 42.31 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ABT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.53  Med: 12.72 Max: 2148.5
Current: 42.31
4.53
2148.5
PB Ratio 2.68
ABT's PB Ratio is ranked higher than
55% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. ABT: 2.68 )
Ranked among companies with meaningful PB Ratio only.
ABT' s PB Ratio Range Over the Past 10 Years
Min: 1.39  Med: 2.32 Max: 3.34
Current: 2.68
1.39
3.34
PS Ratio 3.33
ABT's PS Ratio is ranked lower than
51% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.32 vs. ABT: 3.33 )
Ranked among companies with meaningful PS Ratio only.
ABT' s PS Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.98 Max: 6.24
Current: 3.33
0.96
6.24
Price-to-Free-Cash-Flow 24.53
ABT's Price-to-Free-Cash-Flow is ranked higher than
56% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 32.13 vs. ABT: 24.53 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ABT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.39  Med: 10.14 Max: 40.05
Current: 24.53
4.39
40.05
Price-to-Operating-Cash-Flow 17.95
ABT's Price-to-Operating-Cash-Flow is ranked higher than
52% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 19.50 vs. ABT: 17.95 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ABT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.82  Med: 7.41 Max: 23.85
Current: 17.95
3.82
23.85
EV-to-EBIT 40.65
ABT's EV-to-EBIT is ranked lower than
68% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 24.67 vs. ABT: 40.65 )
Ranked among companies with meaningful EV-to-EBIT only.
ABT' s EV-to-EBIT Range Over the Past 10 Years
Min: -214.2  Med: 18.5 Max: 5424.4
Current: 40.65
-214.2
5424.4
EV-to-EBITDA 21.93
ABT's EV-to-EBITDA is ranked lower than
60% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 17.99 vs. ABT: 21.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 12.9 Max: 28.4
Current: 21.93
4.3
28.4
PEG Ratio 108.86
ABT's PEG Ratio is ranked lower than
96% of the 83 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. ABT: 108.86 )
Ranked among companies with meaningful PEG Ratio only.
ABT' s PEG Ratio Range Over the Past 10 Years
Min: 0.44  Med: 1.39 Max: 140.36
Current: 108.86
0.44
140.36
Shiller PE Ratio 17.78
ABT's Shiller PE Ratio is ranked higher than
94% of the 53 Companies
in the Global Medical Devices industry.

( Industry Median: 49.44 vs. ABT: 17.78 )
Ranked among companies with meaningful Shiller PE Ratio only.
ABT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.03  Med: 12.92 Max: 18.55
Current: 17.78
9.03
18.55
Current Ratio 2.94
ABT's Current Ratio is ranked higher than
55% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.64 vs. ABT: 2.94 )
Ranked among companies with meaningful Current Ratio only.
ABT' s Current Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.33 Max: 4.02
Current: 2.94
0.75
4.02
Quick Ratio 2.41
ABT's Quick Ratio is ranked higher than
57% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ABT: 2.41 )
Ranked among companies with meaningful Quick Ratio only.
ABT' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 0.99 Max: 3.65
Current: 2.41
0.55
3.65
Days Inventory 104.35
ABT's Days Inventory is ranked higher than
61% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 128.08 vs. ABT: 104.35 )
Ranked among companies with meaningful Days Inventory only.
ABT' s Days Inventory Range Over the Past 10 Years
Min: 80.31  Med: 103.72 Max: 145.14
Current: 104.35
80.31
145.14
Days Sales Outstanding 71.63
ABT's Days Sales Outstanding is ranked lower than
55% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. ABT: 71.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.85  Med: 71.85 Max: 145.87
Current: 71.63
56.85
145.87
Days Payable 56.27
ABT's Days Payable is ranked higher than
50% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 54.45 vs. ABT: 56.27 )
Ranked among companies with meaningful Days Payable only.
ABT' s Days Payable Range Over the Past 10 Years
Min: 35.38  Med: 41.44 Max: 73.71
Current: 56.27
35.38
73.71

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.16
ABT's Dividend Yield % is ranked higher than
83% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 1.14 vs. ABT: 2.16 )
Ranked among companies with meaningful Dividend Yield % only.
ABT' s Dividend Yield % Range Over the Past 10 Years
Min: 1.41  Med: 4.82 Max: 7.9
Current: 2.16
1.41
7.9
Dividend Payout Ratio 1.64
ABT's Dividend Payout Ratio is ranked higher than
59% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 0.37 vs. ABT: 1.64 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ABT' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.42  Med: 0.57 Max: 13.4
Current: 1.64
0.42
13.4
3-Year Dividend Growth Rate 22.90
ABT's 3-Year Dividend Growth Rate is ranked higher than
79% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 11.10 vs. ABT: 22.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ABT' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -31.2  Med: 11.5 Max: 22.9
Current: 22.9
-31.2
22.9
Forward Dividend Yield % 2.17
ABT's Forward Dividend Yield % is ranked higher than
82% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 1.51 vs. ABT: 2.17 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.11
ABT's 5-Year Yield-on-Cost % is ranked lower than
62% of the 235 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. ABT: 1.11 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ABT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.72  Med: 2.46 Max: 4.03
Current: 1.11
0.72
4.03
3-Year Average Share Buyback Ratio 1.60
ABT's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. ABT: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: 0.5 Max: 2.2
Current: 1.6
-0.8
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.44
ABT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
78% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. ABT: 1.44 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.36  Med: 0.86 Max: 1.81
Current: 1.44
0.36
1.81
Price-to-Intrinsic-Value-DCF (Earnings Based) 7.12
ABT's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
85% of the 27 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. ABT: 7.12 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.68
ABT's Price-to-Median-PS-Value is ranked lower than
82% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. ABT: 1.68 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.49  Med: 0.83 Max: 3.02
Current: 1.68
0.49
3.02
Price-to-Peter-Lynch-Fair-Value 5.73
ABT's Price-to-Peter-Lynch-Fair-Value is ranked lower than
82% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. ABT: 5.73 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ABT' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.33  Med: 1.01 Max: 6.28
Current: 5.73
0.33
6.28
Earnings Yield (Greenblatt) % 2.46
ABT's Earnings Yield (Greenblatt) % is ranked higher than
63% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. ABT: 2.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1  Med: 4.9 Max: 18.5
Current: 2.46
-1
18.5
Forward Rate of Return (Yacktman) % 17.27
ABT's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.78 vs. ABT: 17.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ABT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -18.6  Med: 13.2 Max: 31.8
Current: 17.27
-18.6
31.8

More Statistics

Revenue (TTM) (Mil) $23,607.00
EPS (TTM) $ 0.71
Beta1.58
Short Percentage of Float1.08%
52-Week Range $37.38 - 51.13
Shares Outstanding (Mil)1,735.27

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 26,677 28,105 29,381
EPS ($) 2.46 2.76 3.09
EPS without NRI ($) 2.46 2.76 3.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.81%
Dividends per Share ($) 1.09 1.15 1.22
» More Articles for ABT

Headlines

Articles On GuruFocus.com
Analysts Release New Ratings on Health Care Stocks Aug 17 2017 
North West London Pathology and Abbott Partner for Diagnostics Products and Services, including Alin Aug 15 2017 
Preferred Stock Purchase Offer Extended Aug 15 2017 
keeley Funds Comments on Abbott Labs Aug 14 2017 
Keeley All Cap Value Fund 2nd Quarter Shareholder Commentary Aug 14 2017 
Abbott Announces Extension of Cash Tender Offer for All Outstanding Shares of Series B Convertible P Aug 14 2017 
The Cost of Malnutrition: Study Shows Nutrition Program Could Save Hospitals up to $3,800 per Patien Aug 10 2017 
Vanguard Health Care Fund Gains 4 International Stocks in 2nd Quarter Aug 04 2017 
Alere Reports 2nd Quarter Aug 04 2017 
What's Behind Thursday's Morning Movements? Jul 20 2017 

More From Other Websites
Abbott-North West London Pathology Expand in Diagnostics Aug 16 2017
North West London Pathology and Abbott Partner for Diagnostics Products and Services, including... Aug 15 2017
Keeley All Cap Value Fund 2nd Quarter Shareholder Commentary Aug 14 2017
Pfizer’s Major Growth Drivers in 2Q17 Aug 14 2017
See what the IHS Markit Score report has to say about Abbott Laboratories. Aug 14 2017
Abbott Announces Extension of Cash Tender Offer for All Outstanding Shares of Series B Convertible... Aug 14 2017
[$$] Investment in Heart Disease Treatments Slips in First Half Aug 14 2017
Edited Transcript of ABT earnings conference call or presentation 20-Jul-17 1:00pm GMT Aug 11 2017
Abbott Laboratories breached its 50 day moving average in a Bearish Manner : ABT-US : August 11,... Aug 11 2017
The Cost of Malnutrition: Study Shows Nutrition Program Could Save Hospitals up to $3,800 per... Aug 10 2017
IHS Markit Score Update: Drop in demand for ETFs holding Abbott Laboratories is a negative sign for... Aug 10 2017
Siemens to update medical scanner software to deal with security bugs Aug 07 2017
No more freebies? India plans crackdown on marketing by drugmakers Aug 02 2017
Healthcare Stocks: Calm After The Storm? Aug 01 2017
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger Jul 26 2017
Analysts Raise Recommendations on Abbott Stock after 2Q17 Jul 26 2017
Abbott Laboratories’ Updated Guidance for 2017 Jul 26 2017
What Were Abbott’s Key Growth Drivers for 2Q17? Jul 25 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}